Inclusion Criteria:

          -  Participants must have histologically documented NSCLC who present with Stage III
             locally advanced, unresectable disease (International Association for the Study of
             Lung Cancer Staging Manual in Thoracic Oncology

          -  Participants with tumor harboring an Epidermal growth factor receptor (EGFR)
             sensitizing (activating) mutation, Anaplastic lymphoma kinase (ALK) translocation,
             ROS-1 rearrangement are eligible.

          -  Participants must have adequate pulmonary function defined as a forced expiratory
             volume in 1 second (FEV1) greater than equals to (>=) 1.2 liters or >= 50% of
             predicted normal volume measured within 3 weeks prior to randomization.

          -  Adequate hematological, hepatic and renal function as defined in the protocol

          -  Contraceptive use by males or females will be consistent with local regulations on
             contraception methods for those participating in clinical studies

        Exclusion Criteria:

          -  Participants with Mixed small cell with non-small cell lung cancer histology

          -  Recent major surgery within 4 weeks prior to entry into the study

          -  Significant acute or chronic infections including human immunodeficiency virus (HIV)
             or known acquired immunodeficiency syndrome, Active hepatitis B virus (HBV) or
             hepatitis C virus (HCV) infection and active tuberculosis

          -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness
             requiring hospitalization

          -  Active autoimmune disease that has required systemic treatment in past 1 year (i.e.,
             with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs)

          -  Any prior systemic cytotoxic chemotherapy for their NSCLC or any antibody or drug
             targeting T-cell coregulatory proteins